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Abstract-The receptor binding profile, composed of the K;-values measured in eight different receptor binding models using rat brain membranes, is reported for the new tricyclic antidepressant quinupramine, 10,11 -dihydro-5-(3-quinuclidinyl) 5H-dibenz [b, f]azepine, and three reference compounds with a tertiaryamine side chain. Quinupramine was found to possess high affinity for muscarinic cholinergic and histamine Ht receptor binding sites in rat brain, whereas its affinity for imipramine binding sites was only one seventieth that of imipramine.
Receptor binding profiles of the reference compounds were almost similar to that of quinupramine , except in the case of imipramine binding sites.
Tricyclic antidepressants
are known to be inhibitors of norepinephrine and serotonin reuptake into nerve terminals. This action was also believed to be responsible for their therapeutic effects and probably involved presynaptic sites (1 were calculated and summarized in Table 2 . Hill coefficients (n1), the slope of the line in the log-logit plot (Hill plot), were calculated by linear regression of the data and also presented in imipramine with K;-values of 20 nM or below, whereas the affinity of quinupramine for the imipramine binding sites (K;=510 nM) was only one seventieth that of imipra mine. Quinupramine also displayed sub stantial affinity for 5-HT2 receptors labelled by[ 3H]spiperone in the cerebral cortex (K;=56 nM, nH=0.27), and it had quite weak affinity for a, -, a2 and 3-adrenergic as well as dopamine D2 receptor binding sites.
The affinity of imipramine and clo mipramine for the muscarinic cholinergic receptors (K;=56 and 55 nM, respectively) was weaker than that of amitriptyline (Ki=5.8 nM) and quinupramine (Ki=2.9 nM).
These tricyclic antidepressants were also potent inhibitors for the binding of to drug-induced side effects. Additionally, the inhibition of monoamine uptake by tricyclic antidepres sants occurs acutely, while the onset of action of all antidepressants is delayed for up to 1 to 3 weeks (I).
It is thus likely that antidepressants may not have a common mechanism of action. On the other hand, depression is not a homogeneous illness (20) , and different antidepressants may be required for different subtypes of depression.
